Samsung Biologics
Global biopharmaceutical CDMO leader based in South Korea
Company Overview
Samsung Biologics is one of the world's largest contract development and manufacturing organizations (CDMO) for biopharmaceuticals. Headquartered in Incheon, South Korea, the company operates the world's largest biomanufacturing capacity and serves global pharmaceutical clients including major Western pharma companies. Samsung Biologics is expanding into biosimilar development and cell & gene therapy manufacturing, positioning itself at the forefront of APAC's biotech manufacturing ecosystem.
Why This Company Matters
Samsung Biologics is the world's largest contract development and manufacturing organization (CDMO) for biologics, playing a critical role in global pharmaceutical supply chains.
Key Focus Areas
Peer Companies
Signal Activity
Signal Timeline
2 totalSamsung Biologics Signs $2.2B CDMO Deal with Major US Pharma Company
Samsung Biologics has signed a $2.2 billion contract development and manufacturing organization (CDMO) deal with an undisclosed major US pharmaceutical company. The multi-year agreement covers biologics manufacturing at Samsung's Songdo campus, which will have total capacity of 784,000 liters upon completion of Plant 4. This is the largest single CDMO contract in the company's history.
Samsung Biologics Achieves Independent Validation for Product Carbon Footprint System
Samsung Biologics has received independent validation for its Product Carbon Footprint (PCF) system, demonstrating its commitment to climate transparency. This validation, achieved through collaboration with an external expert, allows the company to provide customers with accurate carbon footprint data for their products. This initiative supports sustainable supply chain management within the biopharmaceutical industry.
Get notified when new signals are published for this company.